Latest News

While we enjoy watching the progress our portfolio companies make, we appreciate this does not come easily and requires large measures of expertise, intuition, ingenuity and perseverance. This understanding increases our satisfaction in bringing you news of their accomplishments.

Use the filters above to refine results
22nd December 2015

eFFECTOR Therapeutics Raises $40 Million - Series B Financing

21st December 2015

Bayer and CRISPR Therapeutics AG join Forces to Discover, Develop and Commercialize Potential Cures for Serious Genetic Diseases

11th December 2015

CRISPR Therapeutics Appoints Tony Coles to its Board of Directors

11th December 2015

Senseonics Holdings, Inc. and ASN Technologies, Inc. Announce Closing of Merger

3rd December 2015

Cytos Biotechnology and Kuros Biosurgery to combine to create Kuros Biosciences

2nd December 2015

Kesios Therapeutics Raises £19 Million In Series A Financing

17th November 2015

Gynesonics Completes $46 million Equity Financing

12th November 2015

Sientra Appoints Jeffrey Nugent Chairman and Chief Executive Officer

26th October 2015

Vertex and CRISPR Therapeutics Establish Collaboration to Use CRISPR-Cas9 Gene Editing Technology to Discover and Develop New Treatments for Genetic Diseases

20th October 2015

Wilson Therapeutics Appoints Andrew Kay as Chairman

19th October 2015

Abingworth appoints Dr Shelley Chu

9th October 2015

Sientra Sends Letter to Plastic Surgeons Regarding Silimed-Manufactured Products

5th October 2015

Sientra Issues Statement Regarding Recent ANVISA Announcement

24th September 2015

Dear Doctor Letter

18th September 2015

Sientra® Prices Follow-On Public Offering of Common Stock

23rd July 2015

GenSight Biologics Closes $36 Million Series B Preferred Stock Financing

23rd July 2015

SutroVax raises $22 million in Series A

22nd July 2015

Gynesonics Raises $43 million in Equity Financing

7th July 2015

Abingworth appoints Tim Haines and Kurt von Emster as joint Managing Partners

3rd July 2015

MEDIAN Technologies announces a private placement of €19.8 Million at a €12 share price

29th April 2015

CRISPR Therapeutics Raises Additional $64 Million to Translate Breakthrough CRISPR-Cas9 Technology into Next Generation Therapies for Patients

16th March 2015

Chiasma Announces Mark Leuchtenberger as Chief Executive Officer

10th March 2015

Quest Diagnostics to enhance diagnosis of Pediatric Neurological Disorders with exclusive whole exome sequencing from Personalis

10th March 2015

Zogenix Announces Agreement of Sale of Zohydro(R) ER Business to Pernix for $100 Million at Closing Plus Potential Milestones of $283.5 Million

27th February 2015

Chiasma Announces Completion of $70 Million Series E Financing

16th February 2015

U.S. FDA approves anticancer agent LENVIMA™ (Lenvatinib Mesylate) as treatment for Radioactive Iodine-Refracory Differentiated Thyroid Cancer